NuCana plc American Depositary Share

NuCana plc announced the appointment of Theresa Bruce as Chief Operating Officer effective January 1, 2026. Bruce brings over 25 years of experience in oncology R&D and clinical operations. The appointment comes as NuCana plans to advance its pipeline with anticipated data readouts in 2026 for NUC-7738 and further characterization of NUC-3373, wi...

NuCana presented clinical data at ESMO Immuno-Oncology Congress demonstrating promising results for NUC-7738 in treating PD-1 inhibitor-resistant metastatic melanoma, with two partial responses and seven cases of stable disease.

NuCana received a patent from China's National Intellectual Property Administration for NUC-7738, a novel anti-cancer agent currently in Phase 1/2 clinical trials, strengthening its global intellectual property strategy.

NuCana will present research on NUC-7738, a novel anti-cancer agent, at the ESMO Congress 2025 in Berlin, highlighting potential synergies between the drug and PD-1 inhibition in renal cell cancer.

NuCana reported a net loss of £7.0 million for Q2 2024 and had £11.6 million in cash as of June 30, 2024. The company is advancing its clinical programs, including NUC-3373 and NUC-7738, and expects to announce data readouts in the second half of 2024.